A STUDY ON EFFICACY OF PRE-MEDICATIONS IN THE MANAGEMENT OF HYPERSENSITIVITY REACTIONS ASSOCIATED WITH CHEMOTHERAPY AMONG BREAST CANCER PATIENTS

A STUDY ON EFFICACY OF PRE-MEDICATIONS IN THE MANAGEMENT OF HYPERSENSITIVITY REACTIONS ASSOCIATED WITH CHEMOTHERAPY AMONG BREAST CANCER PATIENTS

Registration ID: IJNRD_210856

Published ID: IJNRD2312199

DOI: Click Here to Get

Dr. MUCHUKOTA SUSHMA , PRIYANKA C , SWATHI , ALKAYUM AHMAD , IFTHIKAR, Dr. C D SARASWATHI, SABITHA SUJEETH

Breast cancer, Hypersensitivity reactions, Premedication, Desensitization

ABSTRACT: - Background: The estimation of 2.3 million (11.7% of all cancer cases) new cases of breast cancer diagnosed every year globally, the death rate increased over the last 3 decades, it is the 5th leading cause of mortality worldwide with 685000 deaths. Chemotherapy is a crucial component of breast cancer treatment, yet it is often accompanied by the risk of hypersensitivity reactions (HSRs). Objective: Evaluating hypersensitivity reactions in breast cancer patients involves assessing the effectiveness of premedication, treatment methods, and standardized desensitization protocols to manage reactions and implementing risk management measures. Methodology: This is Hospital based prospective observational study was conducted in ESI hospital Indira nagar Bangalore, the present study was conducted among 85 patients for a period of six months from April 2023 – September 2023, involves breast cancer patients receiving chemotherapy. Results: Among the 85 breast cancer patients in our study, 40% were in stage 2 were classified as having a major disease severity, while only 5.88% of those in stage 4 had the lowest severity. Hypersensitivity reactions were prevalent, with 64.7% experiencing grade Ⅰ and Ⅱ reactions, and 35.29% having grade Ⅲ and Ⅳ reactions. Notably, platinum agents, specifically carboplatin and oxaliplatin, were responsible for hypersensitivity reactions in 54.11% of cases, while taxanes (paclitaxel and docetaxel) were associated with reactions in 32.9% of cases. Additionally, 38% of the participants received monoclonal antibodies as part of their treatment. Conclusion: Breast cancer patients receiving chemotherapy, the present study found significant presence of hypersensitivity reactions, with the majority falling into grade Ⅰ and Ⅱ categories. These reactions were most commonly associated with platinum agents and taxanes. A substantial portion of patients received monoclonal antibodies as part of their treatment. These findings underscore the need for tailored premedication protocols and risk management measures to improve the safety and efficacy of breast cancer therapy, particularly for those at risk of hypersensitivity reactions.

Published Paper   E-Certificate

"A STUDY ON EFFICACY OF PRE-MEDICATIONS IN THE MANAGEMENT OF HYPERSENSITIVITY REACTIONS ASSOCIATED WITH CHEMOTHERAPY AMONG BREAST CANCER PATIENTS", IJNRD - INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (www.IJNRD.org), ISSN:2456-4184, Vol.8, Issue 12, page no.b792-b800, December-2023, Available :https://ijnrd.org/papers/IJNRD2312199.pdf

Volume 8 Issue 12, December-2023

Pages : b792-b800

Paper Reg. ID: IJNRD_210856

Published Paper Id: IJNRD2312199

Downloads: 000121116

Research Area: Engineering

Country: -, -, India

Published Paper PDF: https://ijnrd.org/papers/IJNRD2312199.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2312199

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition

Call For Paper - Volume 10 | Issue 8 | August 2025

IJNRD is Scholarly open access journals, Peer-reviewed, and Refereed Journals, High Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool), Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) with Open-Access Publications.

INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to explore advances in research pertaining to applied, theoretical and experimental Technological studies. The goal is to promote scientific information interchange between researchers, developers, engineers, students, and practitioners working in and around the world. IJNRD will provide an opportunity for practitioners and educators of engineering field to exchange research evidence, models of best practice and innovative ideas.

Indexing In Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar | AI-Powered Research Tool, Microsoft Academic, Academia.edu, arXiv.org, Research Gate, CiteSeerX, ResearcherID Thomson Reuters, Mendeley : reference manager, DocStoc, ISSUU, Scribd, and many more

How to submit the paper?

Important Dates for Current issue

Paper Submission Open For: August 2025

Current Issue: Volume 10 | Issue 8

Last Date for Paper Submission: Till 31-Aug-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: International Peer-reviewed, Refereed, and Open Access Journal.

Subject Category: Research Area